glp 1 drugs pancreatitis Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy Rising Use of GLP-1 Drugs

These phenomena, coupled with the re-development of overweight or obesity and poor glycaemic control when not on therapy, might increase the long-term risk of complications

96 , 97 Cardiovascular safety was first established in the PIONEER 6 trial, 98 with the more recent SOUL trial demonstrating a significant reduction in MACE compared to placebo among individuals with type 2 diabetes and high cardiovascular or renal risk

GLP-1 receptor agonists do not increase the risk of hypoglycemia relative to placebo (48)

in early January 2026

So far, the clinical data are mixed but intriguing

The need for improved efficacy and fewer side effects also potentiates the development of novel drugs